<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636116</url>
  </required_header>
  <id_info>
    <org_study_id>YA-07/02</org_study_id>
    <nct_id>NCT00636116</nct_id>
    <nct_alias>NCT00884156</nct_alias>
  </id_info>
  <brief_title>Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.</brief_title>
  <official_title>A Comparison of Anavip® and CroFab® in the Treatment of Patients With Crotalinae Envenomation: A Randomized, Prospective, Blinded, Controlled, Comparative, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bioclon S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Nacional Autonoma de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Bioclon S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish if F(ab)2 antivenom (Anavip) is safe for crotalinae
      envenomation. Confirm its effectiveness in preventing the occurrence of delayed
      coagulopathies and compare the safety and efficacy with Fab antivenom (CroFab) in patients
      with Crotalinae envenomation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fewer than 200,000 crotaline envenomations occur annually in the US.Crotaline venoms contain
      a broad variety of toxins, venom variability and injection quantity among individual snakes
      and across species result in broadly variable patient presentations. Clinical consequences of
      crotaline envenomation include local and systemic effects, both of which may progress for
      hours to days.The best studied systemic consequence is coagulopathy, which may in its
      complexity mimic disseminated intravascular coagulation. Platelet and clotting disorders
      respond rapidly to administration of polyvalent antivenom.

      Crotaline viper envenomation in the United States is treated with one of two licensed
      products: Wyeth Antivenin (Crotalidae) Polyvalent (Polyvalent), or CroFab® (antivenin
      Crotalidae polyvalent immune Fab, ovine). In recent years, both of these products have been
      in critically short supply. Use of Wyeth Polyvalent has been associated with a greater than
      75% incidence of adverse reactions, including acute type 1 and delayed type 2 immune
      reactions.These phenomena are an inherent risk in the use of whole immunoglobulin. CroFab´s
      low molecular weight creates a pharmacokinetic mismatch with crotaline venom which leds to a
      recurrent venom effects.

      Anavip is pharmacologically and pharmacokinetically different.Because of the elimination of
      the Fc portion of the immunoglobulin molecule, Anavip is expected to produce far fewer
      adverse reactions than seen with whole immunoglobulin antivenoms and unlike Fab molecules,
      F(ab)2 molecules exceed the size threshold for renal clearance and thus are expected to
      remain in circulation for a significantly longer time and substantially reduce the incidence
      of recurrent coagulopathy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of patients experiencing coagulopathy during the follow-up phase of the study. Absolute Platelet levels &lt; 150,000/mm3. Absolute Fibrinogen levels &lt; 150 mg/dL. Clinical coagulopathy requiring additional antivenom.</measure>
    <time_frame>Study Day 5 (±/- 1 day), Study Day 8 (±/- 1 day)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between groups of: Percentage of patients who experience venonemia. Absolute platelet level measured Lowest absolute platelet level measured Absolute fibrinogen level Lowest absolute fibrinogen level</measure>
    <time_frame>Study Day 5 (+/- 1 day) and Study Day 8 (+/- 1 day)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Snake Bite</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anavip with Anavip Maintenance Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anavip with Placebo Maintenance Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CroFab with CroFab Maintenance Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Crotalinae (pit viper) equine immune F(ab)2</intervention_name>
    <description>Anavip with Anavip Maintenance Therapy</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Anavip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Crotalinae (pit viper) equine immune F(ab)2</intervention_name>
    <description>Anavip with Placebo Maintenance Therapy</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Anavip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Crotalidae Polyvalent Immune Fab, ovine</intervention_name>
    <description>CroFab with CroFab Maintenance Therapy</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>CroFab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 2 to 80 years of age

          -  Presenting for emergency treatment of pit viper bite

          -  Informed consent document read and signed by patient (or parent/legal guardian)

        Exclusion Criteria:

          -  Current use of any antivenom, or use within the last month

          -  Current participation in a clinical drug study, or participation within the last month

          -  Positive urine or blood pregnancy test at screening

          -  Breast-feeding

          -  Allergy to horse serum, sheep serum, or papaya

          -  Underlying medical conditions that significantly alter platelet count or fibrinogen;
             thrombocytopenia, hemophilia, familial dysfibrinogenemia, leukemia

          -  Use of any medication expected to affect platelet count, coagulation factors or
             fibrinogen: chemotherapeutic agents, warfarin, heparin

          -  No clinical indications of snake bite requiring antivenom for treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter García Ubbelohde, MD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Bioclon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner Good Samaritan Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maricopa Integrated Health System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tucson Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Physicians Hospital</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Poison Information Center</name>
      <address>
        <city>Jacksonsville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center, Lousiana Poison Control Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of New Mexico Hospital</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt County Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Regional Health Center</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Texas Regional Poison Center at Thomason Hospital</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.redtox.org</url>
    <description>Information about poisonous animals</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>January 9, 2012</last_update_submitted>
  <last_update_submitted_qc>January 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>snake bite</keyword>
  <keyword>antivenin treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Snake Bites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antivenins</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 18, 2016</submitted>
    <returned>April 18, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

